You are viewing a preview of...
High Affinity Ligands that Target Liver Cell Surface Receptor (CD81) and Prevent Malarial Invasion
Compounds bind to cell surface receptor and physically block sporozoites binding to cells or modify the structure of the binding site

Background
Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected anopheles female mosquitoes.
In 2018, malaria caused an estimated 405 000 deaths, mostly among African children (WHO Malaria Report 2018). Increased malaria prevention and control measures are dramatically reducing the malaria burden in many places, however resistance to antimalarial medicines is a recurring problem.
Resistance of P. falciparum to previous generations of medicines, such as chloroquine and sulfadoxine-pyrimethamine (SP), became widespread in the 1970s and 1980s. Oral Artemisinin-based monotherapies are effective in eliminating malaria parasites, and need to be taken as a full seven-day treatment course. However, most patients do not complete the full regimen due to the rapid clinical response
Log in or create a free account to continue reading